3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
Glioblastoma
10
Glioma
7
Astrocytoma
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Brain Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Seroma
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Patient Preference
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Surgical Procedures, Operative
×
Clear all
NCT04770272
2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2
Terminated
442 enrolled
42 charts